Navigation Links
Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Date:6/1/2008

CHICAGO, June 2 /PRNewswire-FirstCall/ -- At the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), two studies were presented investigating the potential utility of Zevalin(R) (Ibritumomab Tiuxetan) radioimmunotherapy as replacement for external beam radiations or supplement to high-dose chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL). Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) markets Zevalin in the United States.

"These two studies add to the increasing body of data suggesting that radioimmunotherapy may be a useful adjunct to stem cell transplantation in late stage non-Hodgkin's lymphoma. It appears not to delay engraftment or add substantially to the toxicities of high dose chemotherapy," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "Controlled studies to determine the actual risk and benefit of RIT in this setting are warranted."

Phase I Trial of (90)Yttrium Ibritumomab Tiuxetan (RIT) with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Abstract 8565

In the phase I trial, 24 relapsed or refractory low-grade B-cell NHL patients, who had received a median of three prior regimens, were treated with escalating doses of RIT based on patient-specific organ dosimetry. Of the 18 patients treated with RIT as single-agent salvage therapy, 13 (72 percent) achieved a complete response (CR) and three patients achieved a partial response (PR). Median time to progression (TTP) was estimated to be nine months, which did not appear to differ regardless of RIT dose. The investigators concluded that patient-specific, organ dosimetry-based significant dose escalation with RIT was achieved with outpatient ASCT su
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
4. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
7. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
8. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
11. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... YORK , June 30, 2015  The Dr. Samadi ... is now offering a full suite of new genetic ... had a biopsy, for diagnosing prostate cancer. ... range of genetic tests for assessing the risk and optimizing ... "We,re very excited to now offer these revolutionary ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today announced a ... archwire that allows orthodontists to simultaneously apply different forces to different teeth. The ... “We’re thrilled about taking SmartArch one step closer to commercial availability for orthodontists ...
(Date:6/29/2015)... ... June 30, 2015 , ... This cutting edge standard making is a ... 12 distinct peaks, the WAV-8 is the world’s first cuvette-shaped, solid-state filter that lets ... the NIR range. Previous spectrophotometer calibration standards, such as those made from didymium glass ...
(Date:6/29/2015)... Lexington, KY and Manhattan, KS (PRWEB) , ... ... ... it has acquired US PATENT 7736892 B2. Under the terms of the agreement, ... using Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development ...
Breaking Biology Technology:New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... with Pfizer,s recently ... MALIBU, Calif., Nov. 15 Pathway Diagnostics announces,that the ... Patent,number 7,294,458 (the ,458 patent) entitled "Analysis of HIV-1 ... Diagnostics,has licensed the ,458 patent (with rights to sub-license) ...
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... George Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary ... Headline Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. ... for drug approvals. Unfortunately for the biopharma sector and,investors, ... is on track,to grant marketing approval to 18 or ...
Cached Biology Technology:Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... an important role in various addictions, such as alcoholism ... is due, in part, to genetic factors, reveals new ... is a neuropeptide that both activates the brain,s reward ... are hungry, levels of ghrelin increase, activating the brain,s ...
... Alberta-led research team has determined that the mountain pine beetle ... possibility for an infestation that could stretch across the Prairies ... of U of A tree biologists and geneticists discovered that, ... Columbia, it successfully jumped species from its main host, the ...
... in the United States in late 2004, many producers feared ... of the world. In response to this threat, researchers have ... fungus, and a recent report in Crop Science ... to determine which of the soybean germplasm accessions were resistant ...
Cached Biology News:Genetic changes behind sweet tooth 2Soybean germplasm evaluations give US a head start against soybean rust pathogen 2Soybean germplasm evaluations give US a head start against soybean rust pathogen 3